BioClinica Responds to Shareholder Letter

BioClinica Responds to Shareholder Letter
-Board Supports Management-

NEWTOWN, Pa., Sep 30, 2010 (BUSINESS WIRE) -- BioClinica(TM), Inc. /quotes/comstock/15*!bioc/quotes/nls/bioc (BIOC 3.52, 0.00, 0.00%) , a global provider of clinical trial management services, has issued the following statement:

The Board of Directors of BioClinica supports management, their extensive industry-specific knowledge, insight and business acumen. The Company has a strategic plan in place to enhance shareholder value, and we are executing upon that plan to build our business and strengthen and expand our suite of services while increasing our operational efficiency. We also have substantial and growing interest in our new eClinical offerings.

Management has always been open to discussions with our shareholders, and it is our intent to continue that dialogue in an effort to facilitate an understanding of our Company, its operations and our strategic growth plan. We are in receipt of a letter from one of our shareholders who has published that letter in the form of a press release. We want to assure our shareholders that the Company remains focused on enhancing long-term shareholder value and delivering high quality clinical trial services to our clients.

About BioClinica, Inc.

BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management services. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica services maximize efficiency and manageability throughout all phases of the clinical trial process. With more than 20 years of experience and over 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit